FDA perspective on specifications for biotechnology products--from IND to PLA

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Quality Control

Background:

• Quality standards are essential for biotechnology-derived products across all development and post-marketing stages.
• Ensuring product identity, purity, and potency requires rigorous quality control measures.

Purpose of the Study:

• To outline a science-based framework for developing and implementing quality standards for biotechnology products.
• To describe the phased approach to setting and refining product specifications.

Main Methods:

• Utilizing experiential data from manufacturing process validation, production consistency, and product characterization.
• Employing a phased framework starting with operational quality limits and progressing to stringent specifications.
• Leveraging historical databases from preclinical and clinical studies for assay method validation and refinement.

Main Results:

• Specifications evolve through distinct phases: initial operational limits, clinical development support, and final licensing/approval.
• Post-approval, ongoing data collection allows for continuous refinement of quality standards.
• Selection of routine testing modalities must consider critical product attributes reflecting identity, purity, and potency.

Conclusions:

• A dynamic, data-driven, and phased approach is necessary for setting and evolving quality standards in biotechnology product development.
• Continuous evaluation and adaptation of specifications based on accumulating data ensure ongoing product quality and safety.
• The framework supports the assurance of identity, purity, and potency from development through post-marketing surveillance.